Non-small-cell lung cancer (NSCLC) is a very common disease in the elderly population
and its incidence in this particular population is expected to increase further, because of the …

Before 2009, nonsmall cell lung cancer (NSCLC) was one disease entity treated by cytotoxic
chemotherapy that provided a response rate of 20–35% and a median survival time (MST) of …

Simple Summary Targeted therapy has become essential in the treatment of non-small cell
lung cancer (NSCLC). There are currently no guidelines for older patients who are frailer …

The use of targeted therapy (TT) has radically changed the outcome of various cancers and
introduces the era of personalised medicine. Elderly patients (≥ 65 years) represent the …

First-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs),
including gefitinib and erlotinib, have proven to be highly effective agents for advanced non …

Background In this prospective non-interventional study, the effectiveness and tolerability of
erlotinib in elderly patients with non-small-cell lung cancer (NSCLC) after≥ 1 platinum …

Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, is an oral targeted
anticancer drug that is used to treat non‑small cell lung cancer (NSCLC). Previous studies …

Objectives The aim of this paper was to investigate the efficacy and activity variation
associated with phosphoinositide 3-kinase (PI3K) signal transduction when combining …

Lung cancer is the leading cause of cancer-associated mortality in the USA. The median
age at diagnosis of lung cancer is 70 years, and thus, about one-half of patients with lung …

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths
worldwide. At diagnosis, half of the patients are over 70 years of age, and most present with …